Tech Company Financing Transactions

Fractyl Laboratories Funding Round

On 8/7/2020, Fractyl Laboratories received $55 million in Series E financing from Taiwania Capital, Bessemer Venture Partners and Catalio Capital Management.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Medical Devices & Instruments

Mailing Address

17 Hartwell Ave.
Lexington, MA 02421
USA

Phone

Undisclosed

Website

www.fractyl.com

Email Address

[email protected]

Overview

Fractyl is developing Revita DMR, a same-day, minimally invasive procedure to treat two highly prevalent metabolic diseases: type 2 diabetes and NAFLD/NASH. The Revita DMR procedure harnesses breakthrough insights in the role of the duodenum in causing insulin resistance and metabolic diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Harith Rajagopalan

        

Chief Financial Officer

Lisa Davidson

        

Chief Medical Officer

Juan Lopez-Talavera

        

President

Jay Caplan

        

Vice President

Kelly White

        

VP - Bus. Development

Margaret Borys

        

VP - Manufacturing

Len Rosberg

        

VP - Regulatory Affairs

Jon Fitzgerald

        

Browse more venture capital transactions:

Prev: 8/7/2020: Aerovate Therapeutics venture capital transaction
Next: 8/7/2020: PandaDoc venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary